Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.

ClinicalTrials.gov 3 recruiting now early-phase tilt small index

Stage IIA Pancreatic Cancer AJCC v8: early-phase trial registry

3 of 8 indexed Stage IIA Pancreatic Cancer AJCC v8 trials are currently recruiting, with more weight in Phase 1-2.

Corpus placement: #2,176 of 28,707 conditions by registered trial count.

8 US clinical trials · 3 currently recruiting · #2,176 of 28,707 conditions by registered trial count

Stage IIA Pancreatic Cancer AJCC v8: 8 US clinical trials tracked, 3 recruiting.

Stage IIA Pancreatic Cancer AJCC v8 is the subject of 8 registered US clinical trials on ClinicalTrials.gov, 3 of them currently open to new participants. 0 are in Phase 3-4 (later-stage) and 7 in Phase 1-2 (earlier-stage). The most active sponsor is Flemming Forsberg, running 1 of these trials.

Enrollment posture brief

Registry condition stage-iia-pancreatic-cancer-ajcc-v8

OPEN 3 | RECR 38% | LATE 0 | EARLY 7 | RANK #2176 | SPON 1

Nearest open-share peer: Acute-graft-versus-host Disease (38% recruiting · 8 trials)

Activity, Motor75%Achalasia50%Stage IIA Pancreatic Can (th…38%Abdominal Cancer25%Acne Scars - Mixed Atrophic 25%
Open-enrollment share among volume-matched conditions near Stage IIA Pancreatic Cancer AJCC v8

Stage IIA Pancreatic Cancer AJCC v8 lists 3 open slots (38% of 8 indexed trials). Peers are matched on registered volume, not therapeutic-area browse lists. How peer matching works →

Key findings

What ClinicalTrials.gov does not surface for Stage IIA Pancreatic Cancer AJCC v8 on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.

  1. Stage IIA Pancreatic Cancer AJCC v8 is recruiting below its size-band peers.

    3 of 8 indexed trials (37.5%) are open to enrollment, against a 46.5% average across 27,806 conditions with fewer than 20 trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.

  2. Sponsorship of Stage IIA Pancreatic Cancer AJCC v8 trials is spread across many organizations.

    Flemming Forsberg accounts for 1 of 8 trials (12.5%). 8 distinct sponsors appear on at least one study for this condition label.

  3. Most Stage IIA Pancreatic Cancer AJCC v8 trials plan to enrol fewer than 100 people.

    Median target enrolment is 28 among the 8 trials that report a genuine target (sentinel values excluded). 6 of those (75%) plan for fewer than 100 participants.

  4. Stage IIA Pancreatic Cancer AJCC v8 research is mostly interventional.

    8 interventional and 0 observational studies make up this index (100% interventional). Study type is sponsor-reported on ClinicalTrials.gov.

Phase 14Phase 23

Open and recent trials

8 total, page 1 of 1

RECRUITING Phase 2 130 participants

Investigational Scan (68Ga-FAPI-46 PET/CT) for Imaging of Cancer-Associated Fibroblasts for Localized Pancreatic Ductal Adenocarcinoma

Mayo Clinic

NCT05518903

RECRUITING NA 60 participants

A Brief Psychological Intervention to Improve Emotional Well-Being During Neoadjuvant Therapy for Pancreatic Cancer

Ohio State University Comprehensive Cancer Center

NCT07124611

RECRUITING Phase 2 28 participants

Lenvatinib and Pembrolizumab Maintenance Therapy for the Treatment of Patients of Advanced Unresectable Pancreatic Cancer

City of Hope Medical Center

NCT04887805

ACTIVE NOT RECRUITING Phase 1 120 participants

Sonoporation and Chemotherapy for the Treatment of Pancreatic Cancer

Flemming Forsberg

NCT04821284

ACTIVE NOT RECRUITING Phase 1 22 participants

Losartan and Hypofractionated Rx After Chemo for Tx of Borderline Resectable or Locally Advanced Unresectable Pancreatic Cancer (SHAPER)

University of Utah

NCT04106856

ACTIVE NOT RECRUITING Phase 1 20 participants

A Study to Determine if the Drug, Pyrvinium Pamoate, is Safe and Tolerable in Patients With Pancreatic Cancer

Thomas Jefferson University

NCT05055323

ACTIVE NOT RECRUITING Phase 1 15 participants

Calaspargase Pegol-Mnkl and Cobimetinib for the Treatment of Locally Advanced or Metastatic Pancreatic Cancer

OHSU Knight Cancer Institute

NCT05034627

ACTIVE NOT RECRUITING Phase 2 13 participants

Gemcitabine, Nab-paclitaxel, Durvalumab, and Oleclumab Before Surgery for the Treatment of in Resectable/Borderline Resectable Primary Pancreatic Cancer

M.D. Anderson Cancer Center

NCT04940286

Phase Distribution

PhaseTrial count
Phase 1 4
Phase 2 3

Named interventions

Most-linked intervention names on Stage IIA Pancreatic Cancer AJCC v8 records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.

Nab-paclitaxel Drug
2 trials
Questionnaire Administration Other
2 trials
Pyrvinium Pamoate Drug
1 trials
Calaspargase Pegol-mknl Drug
1 trials
Losartan Potassium Drug
1 trials
Oleclumab Biological
1 trials
Lenvatinib Mesylate Drug
1 trials
Gallium Ga 68 FAPi-46 Drug
1 trials

US sites by state

Facility locations filed on Stage IIA Pancreatic Cancer AJCC v8 trials. A trial with sites in several states counts in each.

Pennsylvania 2 trials
Utah 1 trials
Texas 1 trials
Oregon 1 trials
Ohio 1 trials
Minnesota 1 trials
California 1 trials

Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.

What to do with this Stage IIA Pancreatic Cancer AJCC v8 page

8 registered trials, 3 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.

  • 3 Stage IIA Pancreatic Cancer AJCC v8 trials are currently recruiting, check eligibility criteria before contacting a site. Browse recruiting trials
  • Flemming Forsberg sponsors the most Stage IIA Pancreatic Cancer AJCC v8 trials on record, review their full trial history before evaluating a specific study. See Flemming Forsberg's trials
  • Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide

Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This Stage IIA Pancreatic Cancer AJCC v8 condition card totals 8 registered trials; most-linked intervention Nab-paclitaxel; top US site state Pennsylvania. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.